You just read:

Boehringer Ingelheim's afatinib Achieves Primary Endpoint in Global Phase III Study in Recurrent/Metastatic Head and Neck Squamous Cell Cancer

News provided by

Boehringer Ingelheim

Sep 27, 2014, 03:00 ET